Gastrointestinal symptoms in patients receiving imeglimin in combination with metformin: A post‐hoc analysis of imeglimin clinical trial data
Increased awareness regarding the potential for GI symptoms, including diarrhea, during imeglimin plus metformin combination therapy is warranted. This data will provide clinicians with useful information regarding symptomatic treatment when it occurs and help determine whether to continue treatment administration and is expected to improve patient adherence.
Authors
- Kohei Kaku (ORCID: https://orcid.org/0000-0003-1574-0565)
- Hirotaka Watada (ORCID: https://orcid.org/0000-0001-5961-1816)
- Jumpei Ito (ORCID: https://orcid.org/0000-0003-0440-8321)
- Katsuhiko Hagi (ORCID: https://orcid.org/0000-0003-1389-1474)
- Kenji Kochi
- Kohjiro Ueki (ORCID: https://orcid.org/0000-0003-1523-8102)
Institutions
- Kawasaki Medical School (JP)
- Sumitomo Dainippon Pharma (Japan) (JP)
- Juntendo University (JP)
- National Center for Global Health and Medicine (JP)
Publication Details
- Journal
- Journal of Diabetes Investigation
- Published
- 2024-12-26
- DOI
- https://doi.org/10.1111/jdi.14396
- Citations
- 2
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.72